AMARIN CORP PLC\UK

AMRN
About the company

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Country: United KingdomPrice: $11.38Market Cap: $478.4M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

3 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2223 (Top 71.8%)NEUTRALFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-02

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 7✗ 21▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.5x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-14.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-14.6%, ROC=-15.6%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)35.2x
      ✗Dreman< 8x
      Price / Book Value per Share0.5x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.5x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low126% of trailing low ($0.45)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-4.00%; #3777/6340 (top 59.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.9289; #1622/6449 (top 25.2%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.53x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-31.0%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.3681; #3032/5247 (top 57.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-21.41%; #4041/6202 (top 65.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -14.0% vs Rev: -22.3%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/17 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-16.9%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency3/5 years with positive EPS growth
      ✓AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 53.9% -> 56.6%, operating margin -22.0% -> -23.5%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR-19.0%
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts0% pass✗ 14▾

      Split decision: 13 FAIL · 3 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)✗GreenblattRank #2223•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)✗TempletonFAIL (2/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 5✗ 30▾

      15 of 16 flag AMRN's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)1/18 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/18 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-10.5%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-23.5% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-116.5M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-4.3%
      ✗Lynch> 15%
      EBIT / Enterprise Value-14.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-14.6%, ROC=-15.6%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-5.78%
      ✗PiotroskiROA > 0
      ROA Change YoY-11.99% -> -5.78% (delta: +6.21%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=1.00%, ROA=-5.78%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY35.6% -> 56.6%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue-9.7%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-4.3%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.5x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-12.0% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/17 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-18.2%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-4.3%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-22.0% (2023) -> -23.5% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 53.9% -> 56.6%, operating margin -22.0% -> -23.5%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-4.00%; #3777/6340 (top 59.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+11.37%; #2708/3702 (top 73.1%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-4.31%; #3175/5226 (top 60.8%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0469; #2500/5884 (top 42.5%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years1/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag AMRN's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities3.50
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-7167.1x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Cash Flow10% pass✓ 2✗ 10▾

      9 of 10 flag AMRN's cash flow — Buffett, Lynch, Dreman +6 more

      Free Cash Flow Proxy$-116.5M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-22.0M
      ✗LynchPositive and growing
      Operating Cash Flow$6.7M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=1.00%, ROA=-5.78%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)35.2x
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/11 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency2/17 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag AMRN's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio3.50
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-48.4%
      ✗Buffett> 10%
      ROIC - WACC-58.4%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-15.6%
      ✗Greenblatt> 25%
      Current Ratio Change YoY3.31 -> 3.34
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.33x -> 0.32x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities3.50
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/1 years above 12% (latest 1.2%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Small Cap($478.4M)
    Revenue: $213.6M-6.5% YoY
    Net Income: $38.8M+52.8% YoY

    Financial Snapshot

    Operating Margin-23.5%
    Return on Equity-8.4%
    Debt / Equity--
    Current Ratio3.34
    EPS (Diluted)$-0.09
    Shares Retired−1.1% / −1.8% 2y

    Shareholder Return

    Fiscal 2025

    Issued 1.1% of shares last year, 1.8% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-02
    FY 2024
    Sources
    • 10-K · 2025-03-12
    FY 2023
    Sources
    • 10-K · 2024-02-29
    FY 2022
    Sources
    • 10-K · 2023-03-01
    FY 2021
    Sources
    • 10-K · 2022-03-01
    Market Cap$478.4Mcurrent------$6.2Best.$4.8Best.$9.2Best.$15.0Best.$28.7Best.
    Revenue$176.1M↓22%$39.5M↓20%$42.2M↓42%$45.1M↑7%$213.6M↓7%$228.6M↓26%$306.9M↓17%$369.2M↓37%$583.2M
    Operating Income-$32.0M↑67%-$2.4M↑79%-$12.0M↑25%-$11.3M↑32%-$50.2M↑45%-$91.8M↓36%-$67.6M↑36%-$105.9M↓1108%$10.5M
    Net Income-$19.1M↑78%$245.0K↑103%-$7.7M↑46%-$10.5M↑33%-$38.8M↑53%-$82.2M↓39%-$59.1M↑44%-$105.8M↓1469%$7.7M
    EPS (Diluted)--$0.00↑100%$-0.02↑33%$-0.03↑25%$-0.09↑55%$-0.20↓33%$-0.15↑42%$-0.26↓1400%$0.02
    Gross Margin40.9%↑5%40.9%↓8%35.5%↓49%39.4%↓34%56.6%↑59%35.6%↓34%53.9%↓18%65.7%↓17%79.2%
    Operating Margin-18.2%↑57%-6.0%↑73%-28.5%↓29%-25.1%↑37%-23.5%↑42%-40.2%↓82%-22.0%↑23%-28.7%↓1692%1.8%
    ROE-4.3%↑77%———-8.4%↑50%-16.9%↓58%-10.7%↑40%-17.8%↓1634%1.2%
    Total Debt----------------$0
    Shareholders' Equity$444.4M↓3%$444.4M↓3%$443.6M↓5%$449.4M↓5%$459.3M↓6%$486.2M↓12%$552.1M↓7%$595.3M↓11%$667.1M
    Current Ratio3.50↑1%3.50↑1%3.67↑12%3.48↓1%3.34↑1%3.31↑18%2.80↑5%2.66↑12%2.37
    Debt / Equity————————0.00
    Operating Cash Flow$37.5M↑272%$9.2M↑173%$6.6M↓60%$6.4M↑151%$6.7M↑122%-$31.0M↓551%$6.9M↑104%-$180.1M↓171%-$66.5M
    Free Cash Flow------------------

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    AMRN vs Peers — Financial Grading

    Revenue$213.6MBottom 25%
    Net Income$38.8MBottom 25%
    ROE-8.4%Bottom 25%
    D/E—
    Op. Margin-23.5%Bottom 25%
    Curr. Ratio3.34Median
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11